Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative.

Tytuł:
The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative.
Autorzy:
Kolaczynska KE; Division of Psychopharmacology Research, Department of Biomedicine, University Hospital Basel and University of Basel, 4031 Basel, Switzerland.
Thomann J; Division of Psychopharmacology Research, Department of Biomedicine, University Hospital Basel and University of Basel, 4031 Basel, Switzerland.
Hoener MC; Neuroscience Research, pRED, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.
Liechti ME; Division of Psychopharmacology Research, Department of Biomedicine, University Hospital Basel and University of Basel, 4031 Basel, Switzerland.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Jul 31; Vol. 22 (15). Date of Electronic Publication: 2021 Jul 31.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
Alkaloids/*chemistry
Dopamine Plasma Membrane Transport Proteins/*antagonists & inhibitors
Norepinephrine Plasma Membrane Transport Proteins/*antagonists & inhibitors
Psychotropic Drugs/*chemistry
Pyrrolidines/*chemistry
Serotonin Plasma Membrane Transport Proteins/*metabolism
Alkaloids/pharmacology ; Biogenic Monoamines/metabolism ; Dopamine Plasma Membrane Transport Proteins/metabolism ; HEK293 Cells ; Humans ; Norepinephrine Plasma Membrane Transport Proteins/metabolism ; Protein Binding ; Psychotropic Drugs/pharmacology ; Pyrrolidines/pharmacology ; Quantitative Structure-Activity Relationship ; Selective Serotonin Reuptake Inhibitors/chemistry ; Selective Serotonin Reuptake Inhibitors/pharmacology
References:
J Neurosci. 2008 Mar 12;28(11):2933-40. (PMID: 18337424)
J Pharmacol Exp Ther. 2012 Feb;340(2):286-94. (PMID: 22034656)
J Pharmacol Exp Ther. 2017 Jan;360(1):33-47. (PMID: 27799294)
J Pharmacol Exp Ther. 2000 Jun;293(3):870-8. (PMID: 10869387)
Handb Exp Pharmacol. 2018;252:113-142. (PMID: 30406443)
Neuropsychopharmacology. 2013 Mar;38(4):552-62. (PMID: 23072836)
Forensic Sci Int. 2014 Oct;243:55-60. (PMID: 24810679)
Neuropsychopharmacology. 2015 May;40(6):1321-31. (PMID: 25502630)
Drug Test Anal. 2011 Jul-Aug;3(7-8):439-53. (PMID: 21755607)
Arch Toxicol. 2020 Apr;94(4):1085-1133. (PMID: 32249347)
Xenobiotica. 2003 Oct;33(10):989-98. (PMID: 14555336)
Int J Neuropsychopharmacol. 2018 Oct 1;21(10):926-931. (PMID: 29850881)
Forensic Sci Int. 2014 Oct;243:23-9. (PMID: 24726531)
Pharmacol Rev. 2016 Apr;68(2):264-355. (PMID: 26841800)
J Pharmacol Exp Ther. 2016 Apr;357(1):134-44. (PMID: 26791601)
J Anal Toxicol. 2012 Jul;36(6):360-71. (PMID: 22586208)
Eur Neuropsychopharmacol. 2020 Apr;33:71-80. (PMID: 32146028)
Soc Cogn Affect Neurosci. 2014 Nov;9(11):1645-52. (PMID: 24097374)
Drug Test Anal. 2014 Jul-Aug;6(7-8):587-97. (PMID: 24995418)
Forensic Sci Int. 2015 Jul;252:168-76. (PMID: 26005857)
Neuropharmacology. 2014 Dec;87:206-13. (PMID: 24594476)
Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. (PMID: 9537821)
Clin Toxicol (Phila). 2011 Jul;49(6):499-505. (PMID: 21824061)
Neuropsychopharmacology. 2020 Feb;45(3):462-471. (PMID: 31733631)
Drug Test Anal. 2017 Aug;9(8):1162-1171. (PMID: 27863142)
Emerg Med J. 2011 Aug;28(8):686-9. (PMID: 20798084)
Br J Pharmacol. 2013 Jan;168(2):458-70. (PMID: 22897747)
Curr Biol. 2017 Feb 6;27(3):451-457. (PMID: 28132813)
J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Aug 15;793(2):331-42. (PMID: 12906908)
Circulation. 2000 Dec 5;102(23):2836-41. (PMID: 11104741)
N Engl J Med. 2011 Sep 8;365(10):967-8. (PMID: 21899474)
J Anal Toxicol. 2013 Apr;37(3):135-46. (PMID: 23361867)
Drug Test Anal. 2013 Jun;5(6):420-9. (PMID: 22549997)
J Neurosci. 2014 Nov 12;34(46):15150-8. (PMID: 25392483)
Neuropharmacology. 2018 May 15;134(Pt A):141-148. (PMID: 28720478)
J Psychopharmacol. 2019 Jul;33(7):831-841. (PMID: 31038382)
J Pharmacol Exp Ther. 2011 Apr;337(1):218-25. (PMID: 21228061)
Forensic Sci Int. 2013 Sep 10;231(1-3):42-53. (PMID: 23890615)
Psychopharmacology (Berl). 2017 Apr;234(8):1237-1245. (PMID: 28210779)
Synapse. 2001 Jan;39(1):32-41. (PMID: 11071707)
J Pharmacol Exp Ther. 2015 Aug;354(2):103-10. (PMID: 25998047)
J Forensic Leg Med. 2019 Jul;65:92-100. (PMID: 31128567)
Exp Neurol. 2021 Sep;343:113778. (PMID: 34090893)
Clin Toxicol (Phila). 2013 Nov;51(9):899-903. (PMID: 24111554)
Br J Pharmacol. 2012 Aug;166(8):2277-88. (PMID: 22404145)
Neuropsychopharmacology. 2012 Apr;37(5):1192-203. (PMID: 22169943)
Forensic Sci Int. 2007 Jun 14;169(1):32-42. (PMID: 16962275)
Drug Test Anal. 2011 Sep;3(9):569-75. (PMID: 21960541)
Neuropsychopharmacology. 2021 Feb;46(3):537-544. (PMID: 33059356)
PLoS One. 2012;7(5):e36476. (PMID: 22574166)
Addiction. 2011 Jan;106(1):154-61. (PMID: 20735367)
Life Sci. 2014 Feb 27;97(1):2-8. (PMID: 23911668)
J Neurosci. 2011 Nov 23;31(47):16928-40. (PMID: 22114263)
Eur Neuropsychopharmacol. 2015 Mar;25(3):365-76. (PMID: 25624004)
Psychopharmacology (Berl). 2019 Mar;236(3):939-952. (PMID: 30397775)
Grant Information:
16.921318 Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Contributed Indexing:
Keywords: cathinone; inhibition; monoamine; novel psychoactive substance; pyrovalerone; receptor; transporter
Substance Nomenclature:
0 (Alkaloids)
0 (Biogenic Monoamines)
0 (Dopamine Plasma Membrane Transport Proteins)
0 (Norepinephrine Plasma Membrane Transport Proteins)
0 (Psychotropic Drugs)
0 (Pyrrolidines)
0 (Serotonin Plasma Membrane Transport Proteins)
0 (Serotonin Uptake Inhibitors)
540EI4406J (cathinone)
VOU69C02JP (pyrovalerone)
Entry Date(s):
Date Created: 20210807 Date Completed: 20210908 Latest Revision: 20221207
Update Code:
20240105
PubMed Central ID:
PMC8348686
DOI:
10.3390/ijms22158277
PMID:
34361040
Czasopismo naukowe
Pyrovalerone cathinones are potent psychoactive substances that possess a pyrrolidine moiety. Pyrovalerone-type novel psychoactive substances (NPS) are continuously detected but their pharmacology and toxicology are largely unknown. We assessed several pyrovalerone and related cathinone derivatives at the human norepinephrine (NET), dopamine (DAT), and serotonin (SERT) uptake transporters using HEK293 cells overexpressing each respective transporter. We examined the transporter-mediated monoamine efflux in preloaded cells. The receptor binding and activation potency was also assessed at the 5-HT 1A , 5-HT 2A , 5-HT 2B , and 5-HT 2C receptors. All pyrovalerone cathinones were potent DAT (IC 50 = 0.02-8.7 μM) and NET inhibitors (IC 50 = 0.03-4.6 μM), and exhibited no SERT activity at concentrations < 10 μM. None of the compounds induced monoamine efflux. NEH was a potent DAT/NET inhibitor (IC 50 = 0.17-0.18 μM). 4F-PBP and NEH exhibited a high selectivity for the DAT (DAT/SERT ratio = 264-356). Extension of the alkyl chain enhanced NET and DAT inhibition potency, while presence of a 3,4-methylenedioxy moiety increased SERT inhibition potency. Most compounds did not exhibit any relevant activity at other monoamine receptors. In conclusion, 4F-PBP and NEH were selective DAT/NET inhibitors indicating that these substances likely produce strong psychostimulant effects and have a high abuse liability.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies